REVIEW SERIES

Challenges in pulmonary fibrosis: 7 · Novel therapies and lung transplantation

T J Williams, J W Wilson

Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Commercial Road, Melbourne 3004, Victoria, Australia

Correspondence to:
Dr J W Wilson, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Commercial Road, Melbourne 3004, Victoria, Australia; john.wilson{at}med.monash.edu.au

The spectrum of diseases collectively known as pulmonary fibrosis does not have reliable therapeutic options. Many treatment protocols have been the subject of clinical trials, resulting in few significant improvements in outcome. Recently, cellular mechanisms have been the focus of investigations in progenitor cell studies, suggesting an immunomodulatory role for mesenchymal stem cells. The possible role of fibrogenic cytokines and the use of antagonist molecules are promising for future therapies. A range of anti-inflammatory treatments, including macrolide antibiotics, may also hold promise. When medical therapy has been unsuccessful in altering the course of the disease, lung transplantation may offer a significant survival advantage. Improvement in pre-transplant assessment and postoperative care, combined with more effective immunosuppressive regimes, has seen survival rates of 40% after 5 years. New options for therapy will lead to improved survival in coming years.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Groves, A. M., Win, T., Screaton, N. J., Berovic, M., Endozo, R., Booth, H., Kayani, I., Menezes, L. J., Dickson, J. C., Ell, P. J. (2009). Idiopathic Pulmonary Fibrosis and Diffuse Parenchymal Lung Disease: Implications from Initial Experience with 18F-FDG PET/CT. JNM 50: 538-545 [Abstract] [Full Text]  
• Lynch, J. P. III (2009). Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia/Fibrosis, and Sarcoidosis. ACCP Pulmonary Med Brd Rev 25: 635-686 [Full Text]  
• Wedzicha, J. A, Johnston, S. L (2008). Thorax update: October 2007-September 2008. Thorax 63: 1036-1037 [Full Text]  
• Williams, T J, Wilson, J W (2008). Authors' reply. Thorax 63: 1121-1121 [Full Text]  
• Maher, T M, Wells, A U (2008). Optimal treatment for idiopathic pulmonary fibrosis. Thorax 63: 1120-1121 [Full Text]  
• Kim, R., Meyer, K. C. (2008). Review: Therapies for interstitial lung disease: past, present and future. Ther Adv Respir Dis 2: 319-338 [Abstract]